Compound huangdai tablet as induction therapy for 193 patients with acute promyelocytic leukemia.
- Author:
Yang XIANG
1
;
Xiao-Bo WANG
;
Shu-Jun SUN
;
Ai-Xia GUO
;
Ai-Hong WEI
;
Yu-Bin CHENG
;
Shi-Lin HUANG
Author Information
- Publication Type:Clinical Trial
- MeSH: Adolescent; Adult; Aged; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; drug therapy; Male; Middle Aged; Phytotherapy; adverse effects; Plant Preparations; adverse effects; therapeutic use; Treatment Outcome; Young Adult
- From: Chinese Journal of Hematology 2009;30(7):440-442
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo report the results of curative and adverse effects of compound huangdai tablet (CHDT) as induction therapy for 193 patients with acute promyelocytic leukemia (APL).
METHODSCHDT was administered 1.25 g orally three times a day after meal for three days, then the dosage was gradually increased to 7.5 g/d.
RESULTSOne hundred and ninety-three patients achieved complete remission (CR), 78.8% of whom in 30 to 60 days with an average time of 44.3 d. No serious infection, bleeding or DIC occurred during the treatment course. The major adverse effects were gastrointestinal symptoms. There was no change in lanine transaminase, urea, creatinine or electrocardiographic QTc interval in 110 APL patients observed before and after the treatment.
CONCLUSIONCHDT therapy is a modality of higher CR rate, good safety and tolerance without bone marrow suppression for APL patients.
